Takeaways: CDA‑AMC’s positive, conditional reimbursement recommendation for Nucala (mepolizumab) in adults with COPD and raised blood eosinophils who remain uncontrolled on ICS/LABA/LAMA triple therap...
Takeaways: If governments adopt the CDA-AMC recommendation, Ubrelvy could gain public coverage and expand AbbVie’s migraine footprint in Canada, creating a stronger commercial path for...
